Bayer announced a five-year partnership with the World Federation of Hemophilia (WFH) Humanitarian Aid Program. According to a Bayer press release, the partnership will allow them to bring education, training, and access to Bayer’s recombinant factor VIII (rFVIII) therapies to healthcare providers in more than 60 countries. The partnership will include a donation of 50 million international units of rFVIII therapies in 2019.
“Three out of four people with bleeding disorders living in developing countries do not have access to adequate treatment, which can have a fatal impact. The WFH Humanitarian Aid Program helps fulfill this urgent and important public health challenge, and its efforts would not be possible without the support of companies such as Bayer,” said Alain Weill, President, World Federation of Hemophilia. “Bayer's contribution to the Program will make a significant difference to nearly 5,000 people living with hemophilia A. Today’s announcement serves as an example of how partnerships enable us to continue providing access to treatment for those in need, regardless of where they live.”
Source: Bayer press release dated May 23, 2019
